期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺表面活性物质的应用及研究进展 被引量：2

原文传递
导出
摘要 肺表面活性物质（pulmonary surfactant，PS）是由脂质（90％）和蛋白质（10％）组成的混合物，由Ⅱ型肺泡细胞分泌，储存于板层小体，通过细胞外分泌的形式分泌后被单层肺泡上皮细胞内表面摄取，并分布于肺泡上皮细胞内表面。目前已发现四种PS载脂蛋白，分别是疏水性表面活性蛋白B（surfactant proteinB，SP-B）、SPC、SP—A及SP—D。通常认为PS具有降低表面张力的特性，可防止肺泡塌陷，有利于气体交换。最新研究还显示PS具有更重要的作用，即肺的天然防御屏障，
作者 刘敬 封志纯
机构地区 北京军区总医院附属八一儿童医院新生儿科
出处 《中华围产医学杂志》 CAS 2009年第5期391-394,共4页 Chinese Journal of Perinatal Medicine
基金 中国博士后科学基金面上资助项目（2008431405）,中国博士后科学基金特别资助项目
关键词 肺表面活性物质 肺泡上皮细胞 表面活性蛋白 细胞分泌 细胞外分泌 SPC 板层小体 载脂蛋白
分类号 R [医药卫生]
  • 相关文献

参考文献41

  • 1Kingma PS, Whitsett JA. Indefense of the lung: surfactant protein A and surfactant protein D. Curr Opin Pharmacol, 2006,6 : 277-283.
  • 2Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol,2005,5:58-68.
  • 3Halliday HL. History of surfactant from 1980. Biol Neonate, 2005,87 : 317-322.
  • 4Mailoy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr, 2005, 94:779- 784.
  • 5Baroutis G, Kaleyias J, Liarou T, et al. Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur J Pediatr, 2003,162 : 476-480.
  • 6Stevens TP, Harrington EW, Blennow M, et al. Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev, 2007, (4):CD003063.
  • 7Verder H. Nasal CPAP has become an indispensable part of the primary treatment of newborns with respiratory distress syndrome. Acta Paediatr, 2007,96:482-484.
  • 8Curstedt T, Johansson J. New synthetic surfactant how and when? Biol Neonate,2006,89:336 -339.
  • 9Moya FR, Gadzinowski J, Bancalari E, et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics, 2005,115:1018-1029.
  • 10Sinha SK, Lacaze-Masmonteil T, Valli S Soler AV, et al. A multicenter randomized, controlled trial of lucinactant versus poraetant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics, 2005, 115: 1030- 1038.

同被引文献21

  • 1陈超.持续呼吸道正压通气在新生儿呼吸系统疾病中的应用[J].实用儿科临床杂志,2007,22(2):86-88. 被引量：108
  • 2邵肖梅,叶鸿瑁,丘小汕.实用新生儿学[M].3版.北京:人民卫生出版社,20i1:384-397.
  • 3中华医学会临床诊疗指南.小儿内科分册[M].2005:43-44.
  • 4Koval'kova NA, Ragino IuI, Logvinenko NI, et al. Significance of surfactant proteins in the diagnosis of therapeutic diseases[ J]. Ter Arkh, 2015, 87 (1): 115-119.
  • 5Han S, Mallampal|i RK. The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections [ J ]. Ann Am Thorac Soc, 2015,12 ( 5 ) :765-774.
  • 6Rugonyi S, Biswas SC, Hall SB. The biophysical function of pulmonary surfactant [ J ]. Respir Physiol Neurobiol, 2008, 163 (1-3) :244-255.
  • 7Pan T, Nielsen LD, Allen MJ, et al. Serum SP-D is a marker of lung injury in rats [ J ]. Am J Physiol Lung Cell Mol Physiol, 2002, 282(4) : L824-L832.
  • 8Bridges JP, Davis HW, Damodarasamy M, et al. Pulmonary surfactant proteins A and D are potent endogenous inhibitors of lipid peroxidation and oxidative cellular injury[ J]. J Biol Chem, 2000, 275 (49) : 38848-38855.
  • 9Clark H, Palaniyar N, Strong P, eta[. Surfactant protein D reduces alveolar macrophage apoptosis in vivo [ J ]. J Immunol, 2002, 169(6) : 2892-2899.
  • 10Willson DF, Thomas N J, Markovitz BP, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial [ J ]. JAMA, 2005, 293 ( 4 ) : 470- 476.

引证文献2

二级引证文献5

中华围产医学杂志
2009年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部